Plato Income Maximiser Limited (ASX:PL8)

Oncternal Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	66.06	65.94	57.36	-12.86	73.02	-21.05
Loss (Gain) From Sale of Investments	-38.05	-38.05	-27.9	109	-74.39	60.72
Other Operating Activities	1.02	-	-	-	-	-
Change in Accounts Receivable	2.65	2.65	10.06	-18.34	2.18	0.17
Change in Accounts Payable	0.12	0.12	0.06	0.1	-0.25	0.35
Operating Cash Flow	43.92	42.77	47.64	44.93	22.84	22.23
Operating Cash Flow Growth	13.38%	-10.22%	6.03%	96.75%	2.72%	-31.70%
Investment in Securities	5.7	-117.94	-93.73	-151.27	-2.32	-142.92
Investing Cash Flow	5.7	-117.94	-93.73	-151.27	-2.32	-142.92
Issuance of Common Stock	-	121.45	85.83	139.36	-	144.38
Common Dividends Paid	-49.41	-46.2	-39.58	-30.63	-20.57	-23.11
Other Financing Activities	-0.03	-0.09	-0.07	-	-	-
Financing Cash Flow	-49.44	75.16	46.19	105.68	-20.57	121.27
Net Cash Flow	0.17	-0	0.1	-0.66	-0.04	0.58
Levered Free Cash Flow	51.73	51.79	51.2	-46.7	61.65	-23.65
Unlevered Free Cash Flow	51.73	51.79	51.2	-46.7	61.65	-23.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.